Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pathology

The Biology of SFT and Your Pathology Report

At a Glance

An SFT pathology report combines the tumor’s microscopic appearance with STAT6 staining and, when needed, molecular testing for the NAB2-STAT6 fusion. Tumor size, mitotic count, necrosis, grade, and margins help estimate recurrence and spread risk.

Because Solitary Fibrous Tumor (SFT) is so rare, getting an accurate diagnosis is the most critical step in your care. Historically, SFT was often confused with other tumors, and it was frequently called hemangiopericytoma (HPC) because of its distinct “staghorn” blood vessel patterns [1][2]. Today, we know that SFT and the tumors formerly called HPC are part of the same disease spectrum, driven by a specific genetic “glitch” [3].

The Biological Driver: NAB2-STAT6

At the heart of almost every SFT is a genetic event called a gene fusion [4]. This happens when two genes on chromosome 12, called NAB2 and STAT6, break and fuse together [3][5].

This new NAB2-STAT6 fusion gene acts like a broken light switch that is stuck in the “on” position. It forces the cells to produce a hybrid protein that enters the cell nucleus and activates other genes (specifically EGR1) that drive the tumor to grow [3][4]. This fusion is a highly characteristic feature of an SFT [6].

The Diagnostic Tests

Because SFT can look like many other types of spindle-cell tumors (such as schwannomas or certain types of liposarcoma), expert pathologists use specialized tests alongside their physical review of the tumor’s appearance (morphology) to confirm the diagnosis [7][8].

  • STAT6 Immunohistochemistry (IHC): This is a highly useful surrogate marker. It uses a special stain to look for the STAT6 protein where it doesn’t belong—inside the cell’s nucleus [8]. In a typical SFT, the report often describes this staining as “strong” and “diffuse” [9].
  • Molecular Testing: If the IHC stain is weak, focal, or negative, or if the tumor looks unusual, doctors may use targeted RNA sequencing or RT-PCR to look for the actual NAB2-STAT6 fusion [5][10]. The diagnosis relies on integrating all these findings, not just a single stain [11].

The Challenge of Dedifferentiation

In some cases, an SFT can become dedifferentiated. This means the tumor cells have lost their original characteristics and turned into a more aggressive, high-grade sarcoma [12][13]. When this happens, the cells may stop producing the STAT6 protein, causing the IHC stain to come back negative [5]. A weak or negative result requires specialist review; they will interpret the stain alongside the specimen’s quality and may use molecular sequencing to look for the underlying fusion gene [11].

Your Pathology Report Checklist

Your pathology report is the roadmap for your treatment. To properly assess the risk of the tumor returning or spreading, the report should contain several key pieces of information [14][10].

Use this checklist to ensure your report is complete:

  • Specimen Type & Primary Site: Is it a biopsy or a complete resection? Where exactly was the tumor located?
  • STAT6 Staining: Confirmation of nuclear STAT6 expression [8].
  • Tumor Size: The greatest dimension of the tumor in centimeters [15].
  • Mitotic Count: A measure of how fast the cells are dividing, usually listed as the number of mitoses per 10 high-power fields (HPF) or per mm2mm^2 [16].
  • Necrosis: Whether “dead” tumor tissue is present or absent (or a percentage). This can indicate a tumor is growing faster than its blood supply [17].
  • Margins: Whether the edges of the removed tissue are “clear” (negative) or “involved” (positive), and the exact orientation and distance (in millimeters) from the tumor to the closest edge [18].
  • Dedifferentiation/Histologic Grade: A clear statement on whether any high-grade or atypical areas were found [13].

Risk Stratification

Rather than simply labeling a tumor “benign” or “malignant,” modern medicine uses risk-stratification models to predict metastasis, such as the Demicco model [15]. The pathologist reports the inputs (like age, size, mitotic count, and necrosis), and the multidisciplinary team uses these variables to place you into a risk category [14][17]. Local recurrence also depends on the tumor’s site, margins, and surgical approach [10]. Because this assessment is complex, it is essential that your pathology is reviewed by an expert who specializes in rare soft-tissue tumors [19].

Common questions in this guide

What does strong, diffuse nuclear STAT6 staining mean on an SFT pathology report?
Strong, diffuse STAT6 staining in the cell nucleus supports a diagnosis of solitary fibrous tumor because the NAB2-STAT6 gene fusion commonly causes this pattern. The stain is interpreted together with the tumor’s appearance under the microscope and other test results, rather than used by itself.
Can a solitary fibrous tumor have a weak or negative STAT6 test?
Yes. STAT6 staining can be weak or negative when an SFT is unusual, dedifferentiated, or the specimen is not ideal for testing. A specialist may review the tissue and recommend molecular testing, such as RNA sequencing or RT-PCR, to look for the NAB2-STAT6 fusion.
What information should be included in an SFT pathology report?
The report should identify the specimen type and tumor location, size, STAT6 result, mitotic count, necrosis, surgical margins, and any dedifferentiated or high-grade areas. These details help the care team estimate the risk of recurrence or spread and plan follow-up.
What is the NAB2-STAT6 fusion in solitary fibrous tumor?
The NAB2-STAT6 fusion is a genetic change in which parts of two genes join together. It produces a combined protein that can activate growth-related genes and is a highly characteristic finding in solitary fibrous tumor.
How is the risk of an SFT spreading or returning estimated?
Doctors may use the Demicco model, which considers factors such as age, tumor size, mitotic count, and necrosis to estimate the risk of metastasis. The tumor’s location, surgical margins, and the way it was removed also influence the risk of local recurrence.
Should my SFT pathology be reviewed by a sarcoma specialist?
Expert review is especially valuable because SFT can resemble other spindle-cell tumors and is rare. A pathologist who specializes in soft-tissue tumors can interpret the microscope findings, STAT6 result, and any molecular testing together.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has this pathology been reviewed by a specialized soft-tissue or sarcoma pathologist?
  2. 2.Does my report confirm 'strong, diffuse nuclear staining' for STAT6?
  3. 3.What is my risk score according to the Demicco model, and how does my age and tumor size factor into that?
  4. 4.If my STAT6 test was negative or weak, was targeted RNA sequencing performed to look for the NAB2-STAT6 fusion?
  5. 5.What is the exact mitotic count listed in my report, and how does that affect my follow-up schedule?
  6. 6.Are the surgical margins 'clear,' and what is the exact distance (in millimeters) from the tumor to the edge of the tissue?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics.

    Thway K, Ng W, Noujaim J, et al.

    International journal of surgical pathology 2016; (24(4)):281-92 doi:10.1177/1066896915627485.

    PMID: 26811389
  2. 2

    Solitary Fibrous Tumor/Hemangiopericytoma Dichotomy Revisited: A Restless Family of Neoplasms in the CNS.

    Yalcin CE, Tihan T

    Advances in anatomic pathology 2016; (23(2)):104-11 doi:10.1097/PAP.0000000000000103.

    PMID: 26849816
  3. 3

    Clinicopathological differences between variants of the NAB2-STAT6 fusion gene in solitary fibrous tumors of the meninges and extra-central nervous system.

    Nakada S, Minato H, Nojima T

    Brain tumor pathology 2016; (33(3)):169-74 doi:10.1007/s10014-016-0264-6.

    PMID: 27271270
  4. 4

    Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants.

    Bieg M, Moskalev EA, Will R, et al.

    The American journal of pathology 2021; (191(4)):602-617 doi:10.1016/j.ajpath.2020.12.015.

    PMID: 33497701
  5. 5

    The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing.

    Guseva NV, Tanas MR, Stence AA, et al.

    Cancer genetics 2016; (209(7-8)):303-12.

    PMID: 27292373
  6. 6

    Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications.

    Ren C, D'Amato G, Hornicek FJ, et al.

    Cancer metastasis reviews 2024; (43(4)):1337-1352 doi:10.1007/s10555-024-10204-8.

    PMID: 39120790
  7. 7

    The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior.

    Tariq MU, Din NU, Abdul-Ghafar J, Park YK

    Diagnostic pathology 2021; (16(1)):32 doi:10.1186/s13000-021-01095-2.

    PMID: 33879215
  8. 8

    STAT6 Expression in Solitary Fibrous Tumor and Histologic Mimics: a Single Institution Experience.

    Saeed O, Zhang S, Cheng L, et al.

    Applied immunohistochemistry & molecular morphology : AIMM 2020; (28(4)):311-315 doi:10.1097/PAI.0000000000000745.

    PMID: 30664532
  9. 9

    Differential diagnosis of solitary fibrous tumors: A study of 454 soft tissue tumors indicating the diagnostic value of nuclear STAT6 relocation and ALDH1 expression combined with in situ proximity ligation assay.

    Ouladan S, Trautmann M, Orouji E, et al.

    International journal of oncology 2015; (46(6)):2595-605 doi:10.3892/ijo.2015.2975.

    PMID: 25901508
  10. 10

    Toward Better Understanding and Management of Solitary Fibrous Tumor.

    Kazazian K, Demicco EG, de Perrot M, et al.

    Surgical oncology clinics of North America 2022; (31(3)):459-483 doi:10.1016/j.soc.2022.03.009.

    PMID: 35715145
  11. 11

    Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

    Dagrada GP, Spagnuolo RD, Mauro V, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(8)):1074-83 doi:10.1038/modpathol.2015.70.

    PMID: 26022454
  12. 12

    Solitary fibrous tumor: An evolving and unifying entity with unsettled issues.

    Huang SC, Huang HY

    Histology and histopathology 2019; (34(4)):313-334 doi:10.14670/HH-18-064.

    PMID: 30431144
  13. 13

    Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death.

    Yamada Y, Kohashi K, Kinoshita I, et al.

    Virchows Archiv : an international journal of pathology 2019; (475(4)):467-477 doi:10.1007/s00428-019-02622-9.

    PMID: 31392468
  14. 14

    Solitary fibrous tumor of kidney and renal hilus: a multi-institutional clinicopathologic analysis of 43 cases.

    Güner G, Akgul M, Michal M, et al.

    Virchows Archiv : an international journal of pathology 2025; (487(6)):1265-1278 doi:10.1007/s00428-025-04264-6.

    PMID: 40965627
  15. 15

    Prognostic usefulness of a modified risk model for solitary fibrous tumor that includes the Ki-67 labeling index.

    Sugita S, Segawa K, Kikuchi N, et al.

    World journal of surgical oncology 2022; (20(1)):29 doi:10.1186/s12957-022-02497-2.

    PMID: 35105348
  16. 16

    Risk factors for recurrent disease after resection of solitary fibrous tumor: a systematic review.

    Tolstrup J, Loya A, Aggerholm-Pedersen N, et al.

    Frontiers in surgery 2024; (11()):1332421 doi:10.3389/fsurg.2024.1332421.

    PMID: 38357190
  17. 17

    Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient outcome.

    Machado I, Nieto Morales MG, Cruz J, et al.

    International journal of molecular sciences 2021; (22(17)) doi:10.3390/ijms22179423.

    PMID: 34502329
  18. 18

    Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance.

    Matthijs V, Beckers R, Broecke CV, et al.

    Acta neurochirurgica 2024; (166(1)):414 doi:10.1007/s00701-024-06304-7.

    PMID: 39417883
  19. 19

    An Unexpected Finding of an Aggressive Pleural Hemangiopericytoma/Solitary Fibrous Tumor in a Patient With Recurrent Meningioma: A Case Report.

    Basir S, Bosiers J, van Walree NC

    Cureus 2024; (16(2)):e54965 doi:10.7759/cureus.54965.

    PMID: 38544608

This page explains SFT biology and pathology report terms for informational purposes only; it does not constitute medical advice. Ask a sarcoma pathologist or treating team to interpret your report and risk category.

Get notified when new evidence is published on Solitary Fibrous Tumor (SFT).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.